Elevate your Research with AI-Powered Digital Pathology
From Pre-clinical research to late-stage clinical trials, HistoIndex provides cutting-edge, stain-free digital pathology solutions that enhance precision and drive successful outcomes.
Advanced Stain-Free Imaging Technology
Supplementing Second Harmonic Generation microscopy with AI assessments, our platforms analyze liver biopsies to accurately quantify fibrosis – unlocking continuous metrics that sensitively detect subtle histological changes that may be missed by stains.
With over a decade of expertise, we have scanned and analyzed more than 10,000 patient biopsy samples from MASH clinical trials in collaboration with leading pharma and biotech partners, often revealing insights of drug action not detectable by standard assessments.
Refer to our publications page here.
Pre-Clinical Studies
Achieve greater accuracy, reproducibility, and efficiency in your preclinical studies, accelerating the path to clinical success.
- Early & Accurate Disease Detection – Identify minute pathological changes in MASH and other disease models with a fail-fast system
- AI-Powered Quantitative Digital Pathology – Continuous, stain-free measurement of fibrosis, septa, steatosis, and ballooning for precise histology-based assessment
- Zonal & Localization Analysis – Gain deeper understanding into disease progression and drug mechanisms of action with spatial insights
- Seamless Preclinical-to-Clinical Transition – Ensure consistency with an AI-based platform that translates findings from animal models to human biopsy quantification
Clinical Studies
HistoIndex collaborates with leading pharmaceutical players, biotech companies, and research institutes to drive mechanistic and biomarker discovery through AI-powered analysis. Enabled by our sensitive stain-free imaging, our fully quantitative and granular analysis of generated histology images offers deep understanding into fibrosis regression, disease progression prediction, and clinical outcome assessments.
Our stain-free, AI-based platform supports both academic and industry-sponsored clinical studies, ensuring seamless data translation across biomarker discovery and drug development phases.
Clinical Trials
We are powering clinical trials with AI-driven digital pathology to enhance drug evaluation and regulatory success.
HistoIndex is a trusted partner in clinical trials, contributing to FDA Phase 2b/3 MASH trials. Our stain-free, AI-based platform has been utilized as primary, secondary, and exploratory endpoints in leading studies
Why Integrate AI Digital Pathology into Your Trials?
- Endpoint Quantification & Biomarker Discovery
- Provide robust, quantitative data to support regulatory approvals.
- Improve pathologist reproducibility in staging/scoring, especially in borderline cases
- Reduce “no change” cases and increase measurable treatment response
Our technology eliminates inter-reader variability and enhances reproducibility in histological assessments. By providing objective, quantitative endpoints, we help accelerate decision-making and reduce trial risk—unlocking the full potential of your investigational therapy.